Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management in Total Knee Arthroplasty

NCT06509958 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06509958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06509958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management in Total Knee Arthroplasty
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
August 20, 2024
Completion date
October 10, 2024
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postoperative pain management in total knee arthroplasty